NDA[removed] – FDA Approved Labeling Text dated January[removed]MEDICATION GUIDE AMPYRA® (am-PEER-ah) - Alkermes - Document - PDFSEARCH.IO

First Page		Document Content
Clinical pharmacology Amines 4-Aminopyridine Pyridines Acorda Therapeutics Alkermes Prescription medication Package insert Medical prescription Pharmaceutical sciences Medicine Pharmacology		NDA[removed] – FDA Approved Labeling Text dated January[removed]MEDICATION GUIDE AMPYRA® (am-PEER-ah) Add to Reading List Source URL: www.fda.gov Download Document from Source Website File Size: 127,14 KB Share Document on Facebook

	Microsoft WordFampridine FAMPYRA Biogen IdecPSD FINAL.doc DocID: 18vGz - View Document
	Clinical Commissioning Policy Statement: Fampridine for Multiple Sclerosis (MS) April 2013 DocID: 18tyj - View Document
	ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of DocID: XxYA - View Document
	Acknowledgement We acknowledge and pay respect to the traditional custodians past and present on whose lands we meet today. We acknowledge the deep feelings of attachment DocID: WFCH - View Document
	HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AMPYRA safely and effectively. See full prescribing information for AMPYRA. AMPYRA® (dalfampridine) Extended Releas DocID: Ra4U - View Document